NO328680B1 - Anvendelse av oral poliovirusvaksine (OPV) og ikke-polio enterovirusvaksine mot ikke-polio virussykdommer slik som type 1 diabetes og et vaksinepreparat omfattende nevnte virus. - Google Patents

Anvendelse av oral poliovirusvaksine (OPV) og ikke-polio enterovirusvaksine mot ikke-polio virussykdommer slik som type 1 diabetes og et vaksinepreparat omfattende nevnte virus. Download PDF

Info

Publication number: NO328680B1
Authority: NO; Norway
Prior art keywords: vaccine; serotypes; enterovirus; polio; opv
Prior art date: 1999-06-24

Application number

NO20016211A

Other languages

English (en)

Norwegian (no)

Other versions

NO20016211D0 (no

NO20016211L (no

Inventor

Heikki Hyoty

Mikael Knip

Original Assignee

Heikki Hyoty

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-24

Filing date

2001-12-18

Publication date

2010-04-26

2001-12-18 Application filed by Heikki Hyoty filed Critical Heikki Hyoty

2001-12-18 Publication of NO20016211D0 publication Critical patent/NO20016211D0/no

2002-02-20 Publication of NO20016211L publication Critical patent/NO20016211L/no

2010-04-26 Publication of NO328680B1 publication Critical patent/NO328680B1/no

Links

229960005486 vaccine Drugs 0.000 title claims abstract description 151
241000709661 Enterovirus Species 0.000 title claims abstract description 106
208000000474 Poliomyelitis Diseases 0.000 title claims abstract description 88
206010067584 Type 1 diabetes mellitus Diseases 0.000 title claims abstract description 61
229940124867 Poliovirus vaccine Drugs 0.000 title claims abstract description 39
201000010099 disease Diseases 0.000 title claims abstract description 37
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 37
241000700605 Viruses Species 0.000 title abstract description 46
241000991587 Enterovirus C Species 0.000 title description 40
239000000203 mixture Substances 0.000 title description 5
229940031626 subunit vaccine Drugs 0.000 claims abstract description 24
230000036039 immunity Effects 0.000 claims description 26
238000004519 manufacturing process Methods 0.000 claims description 19
230000001939 inductive effect Effects 0.000 claims description 15
241000709687 Coxsackievirus Species 0.000 claims description 10
239000000427 antigen Substances 0.000 claims description 9
108091007433 antigens Proteins 0.000 claims description 9
102000036639 antigens Human genes 0.000 claims description 9
241001466953 Echovirus Species 0.000 claims description 7
241000988559 Enterovirus A Species 0.000 claims description 7
230000001904 diabetogenic effect Effects 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 6
239000003999 initiator Substances 0.000 claims 1
230000004044 response Effects 0.000 abstract description 27
230000000694 effects Effects 0.000 abstract description 25
230000028993 immune response Effects 0.000 abstract description 25
230000002265 prevention Effects 0.000 abstract description 15
230000009931 harmful effect Effects 0.000 abstract description 7
230000002238 attenuated effect Effects 0.000 abstract description 6
230000002939 deleterious effect Effects 0.000 abstract description 2
229960005030 other vaccine in atc Drugs 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 description 43
238000002255 vaccination Methods 0.000 description 37
206010014909 Enterovirus infection Diseases 0.000 description 35
208000012022 enterovirus infectious disease Diseases 0.000 description 31
230000005867 T cell response Effects 0.000 description 25
241000709675 Coxsackievirus B3 Species 0.000 description 23
210000001744 T-lymphocyte Anatomy 0.000 description 20
238000002649 immunization Methods 0.000 description 20
230000003053 immunization Effects 0.000 description 20
230000003472 neutralizing effect Effects 0.000 description 19
241000699670 Mus sp. Species 0.000 description 17
230000006698 induction Effects 0.000 description 13
206010012601 diabetes mellitus Diseases 0.000 description 11
230000000890 antigenic effect Effects 0.000 description 10
230000009471 action Effects 0.000 description 9
230000005875 antibody response Effects 0.000 description 9
241000274177 Juniperus sabina Species 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 8
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
229940031551 inactivated vaccine Drugs 0.000 description 8
230000001965 increasing effect Effects 0.000 description 8
238000000034 method Methods 0.000 description 8
239000002953 phosphate buffered saline Substances 0.000 description 8
241000282414 Homo sapiens Species 0.000 description 7
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
241000282412 Homo Species 0.000 description 6
241000709701 Human poliovirus 1 Species 0.000 description 6
206010058874 Viraemia Diseases 0.000 description 6
230000002458 infectious effect Effects 0.000 description 6
201000001320 Atherosclerosis Diseases 0.000 description 5
201000009906 Meningitis Diseases 0.000 description 5
208000009525 Myocarditis Diseases 0.000 description 5
241000725643 Respiratory syncytial virus Species 0.000 description 5
230000006052 T cell proliferation Effects 0.000 description 5
108010067390 Viral Proteins Proteins 0.000 description 5
239000002299 complementary DNA Substances 0.000 description 5
230000009260 cross reactivity Effects 0.000 description 5
230000001186 cumulative effect Effects 0.000 description 5
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
230000008029 eradication Effects 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
210000003071 memory t lymphocyte Anatomy 0.000 description 5
208000025223 poliovirus infection Diseases 0.000 description 5
230000001681 protective effect Effects 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
238000011725 BALB/c mouse Methods 0.000 description 4
208000010201 Exanthema Diseases 0.000 description 4
208000007212 Foot-and-Mouth Disease Diseases 0.000 description 4
241000710198 Foot-and-mouth disease virus Species 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
206010033799 Paralysis Diseases 0.000 description 4
201000005884 exanthem Diseases 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
229940029583 inactivated polio vaccine Drugs 0.000 description 4
230000008595 infiltration Effects 0.000 description 4
238000001764 infiltration Methods 0.000 description 4
210000000496 pancreas Anatomy 0.000 description 4
206010037844 rash Diseases 0.000 description 4
210000004291 uterus Anatomy 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 3
241000709673 Coxsackievirus B4 Species 0.000 description 3
206010033645 Pancreatitis Diseases 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000000969 carrier Substances 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000012634 fragment Substances 0.000 description 3
210000001035 gastrointestinal tract Anatomy 0.000 description 3
210000000936 intestine Anatomy 0.000 description 3
239000007927 intramuscular injection Substances 0.000 description 3
238000010255 intramuscular injection Methods 0.000 description 3
230000007108 local immune response Effects 0.000 description 3
229940041323 measles vaccine Drugs 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 3
230000001769 paralizing effect Effects 0.000 description 3
201000006995 paralytic poliomyelitis Diseases 0.000 description 3
239000002245 particle Substances 0.000 description 3
229960001539 poliomyelitis vaccine Drugs 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
238000011282 treatment Methods 0.000 description 3
108700028369 Alleles Proteins 0.000 description 2
206010056370 Congestive cardiomyopathy Diseases 0.000 description 2
201000010046 Dilated cardiomyopathy Diseases 0.000 description 2
201000006219 Herpangina Diseases 0.000 description 2
241000709704 Human poliovirus 2 Species 0.000 description 2
241000709727 Human poliovirus 3 Species 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
206010035623 Pleuritic pain Diseases 0.000 description 2
206010035664 Pneumonia Diseases 0.000 description 2
208000035415 Reinfection Diseases 0.000 description 2
230000024932 T cell mediated immunity Effects 0.000 description 2
108020000999 Viral RNA Proteins 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000002411 adverse Effects 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
208000037887 cell injury Diseases 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
210000004837 gut-associated lymphoid tissue Anatomy 0.000 description 2
208000006454 hepatitis Diseases 0.000 description 2
231100000283 hepatitis Toxicity 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000000415 inactivating effect Effects 0.000 description 2
230000008774 maternal effect Effects 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
230000008506 pathogenesis Effects 0.000 description 2
108010048507 poliovirus receptor Proteins 0.000 description 2
230000035935 pregnancy Effects 0.000 description 2
230000003449 preventive effect Effects 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
230000005180 public health Effects 0.000 description 2
210000000664 rectum Anatomy 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000010076 replication Effects 0.000 description 2
208000023504 respiratory system disease Diseases 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
208000006740 Aseptic Meningitis Diseases 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
102000009016 Cholera Toxin Human genes 0.000 description 1
108010049048 Cholera Toxin Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
241000712079 Measles morbillivirus Species 0.000 description 1
206010027201 Meningitis aseptic Diseases 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
206010061308 Neonatal infection Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
238000011803 SJL/J (JAX™ mice strain) Methods 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000007815 allergy Effects 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
210000000234 capsid Anatomy 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000000703 high-speed centrifugation Methods 0.000 description 1
230000004727 humoral immunity Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000015788 innate immune response Effects 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
229960002337 magnesium chloride Drugs 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000012768 mass vaccination Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
239000000693 micelle Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
210000004457 myocytus nodalis Anatomy 0.000 description 1
229940127241 oral polio vaccine Drugs 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
210000003800 pharynx Anatomy 0.000 description 1
229960003742 phenol Drugs 0.000 description 1
229960005323 phenoxyethanol Drugs 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000037452 priming Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000003757 reverse transcription PCR Methods 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229960004906 thiomersal Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
210000000605 viral structure Anatomy 0.000 description 1
230000001018 virulence Effects 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32311—Enterovirus
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32311—Enterovirus
- C12N2770/32334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Mycology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20016211A 1999-06-24 2001-12-18 Anvendelse av oral poliovirusvaksine (OPV) og ikke-polio enterovirusvaksine mot ikke-polio virussykdommer slik som type 1 diabetes og et vaksinepreparat omfattende nevnte virus. NO328680B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US14087299P	1999-06-24	1999-06-24
PCT/FI2000/000220 WO2001000236A1 (en)	1999-06-24	2000-03-17	Prevention of type 1 diabetes and other non-polio enterovirus diseases

Publications (3)

Publication Number	Publication Date
NO20016211D0 NO20016211D0 (no)	2001-12-18
NO20016211L NO20016211L (no)	2002-02-20
NO328680B1 true NO328680B1 (no)	2010-04-26

Family

ID=22493179

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20016211A NO328680B1 (no)	1999-06-24	2001-12-18	Anvendelse av oral poliovirusvaksine (OPV) og ikke-polio enterovirusvaksine mot ikke-polio virussykdommer slik som type 1 diabetes og et vaksinepreparat omfattende nevnte virus.

Country Status (10)

Country	Link
EP (1)	EP1187631B1 (de)
AT (1)	ATE276761T1 (de)
AU (1)	AU770922B2 (de)
CA (1)	CA2376923C (de)
DE (1)	DE60014077T2 (de)
DK (1)	DK1187631T3 (de)
ES (1)	ES2228481T3 (de)
NO (1)	NO328680B1 (de)
PT (1)	PT1187631E (de)
WO (1)	WO2001000236A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8961982B2 (en) *	2005-12-16	2015-02-24	The Regents Of The University Of California	Modulation of developmental immune programming and protection against cardiovascular disease, diabetes, infectious diseases, and cancer
FI20075063A0 (fi) *	2007-02-01	2007-02-01	Vactech Oy	Allergisen herkistymisen estäminen
FI20075861A0 (fi)	2007-11-30	2007-11-30	Vactech Oy	Enteroviruksen käyttö taudin diagnostiikassa, hoidossa ja ehkäisyssä
US20110245179A1 (en) *	2008-09-17	2011-10-06	Woo Jin Park	Composition for Prevention or Treatment of Heart Failure
EP2402029A1 (de)	2010-07-01	2012-01-04	Sanofi Pasteur	Enterovirus-Impfstoffe zur Vorbeugung oder Behandlung von Typ-1-Diabetes (III)
EP2402027A1 (de)	2010-07-01	2012-01-04	Sanofi Pasteur	Enterovirus-Impfstoffe zur Vorbeugung oder Behandlung von Typ-1-Diabetes (I)
EP2588134B1 (de)	2010-07-01	2016-10-26	Vactech OY	Diagnostischer test für typ-1-diabetes
EP2402028A1 (de)	2010-07-01	2012-01-04	Sanofi Pasteur	Enterovirus-Impfstoffe zur Vorbeugung und Behandlung von Typ-1-Diabetes (II)
EP2583688A1 (de)	2011-10-18	2013-04-24	Sanofi Pasteur	Multi-CBV-Impfstoffe zur Vorbeugung oder Behandlung von Typ-1-Diabetes
DK2780067T3 (da)	2011-11-18	2021-08-16	Colin Dunlop	Anæstetisk genåndingskredsløb
US20140271718A1 (en)	2013-03-15	2014-09-18	University Of Florida Research Foundation Incorporated	Novel type 1 diabetes vaccines, and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5728385A (en) *	1993-08-12	1998-03-17	Classen Immunotherapies, Inc.	Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae

2000
- 2000-03-17 ES ES00912706T patent/ES2228481T3/es not_active Expired - Lifetime
- 2000-03-17 DE DE60014077T patent/DE60014077T2/de not_active Expired - Lifetime
- 2000-03-17 WO PCT/FI2000/000220 patent/WO2001000236A1/en not_active Ceased
- 2000-03-17 DK DK00912706T patent/DK1187631T3/da active
- 2000-03-17 CA CA2376923A patent/CA2376923C/en not_active Expired - Fee Related
- 2000-03-17 EP EP00912706A patent/EP1187631B1/de not_active Expired - Lifetime
- 2000-03-17 AU AU34366/00A patent/AU770922B2/en not_active Ceased
- 2000-03-17 PT PT00912706T patent/PT1187631E/pt unknown
- 2000-03-17 AT AT00912706T patent/ATE276761T1/de active
2001
- 2001-12-18 NO NO20016211A patent/NO328680B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
NO20016211D0 (no)	2001-12-18
AU770922B2 (en)	2004-03-11
DE60014077D1 (de)	2004-10-28
DE60014077T2 (de)	2005-10-20
WO2001000236A1 (en)	2001-01-04
ES2228481T3 (es)	2005-04-16
CA2376923A1 (en)	2001-01-04
EP1187631A1 (de)	2002-03-20
NO20016211L (no)	2002-02-20
CA2376923C (en)	2014-08-05
PT1187631E (pt)	2005-01-31
EP1187631B1 (de)	2004-09-22
AU3436600A (en)	2001-01-31
DK1187631T3 (da)	2005-01-24
ATE276761T1 (de)	2004-10-15

Legal Events

Date	Code	Title	Description
2014-11-03	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US12329813B2 (en)	2025-06-17	Porcine epidemic diarrhea virus strains and immunogenic compositions therefrom
Foo et al.	2007	Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide
Chung et al.	2008	Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge
RU2561595C2 (ru)	2015-08-27	Вакцина против высокопатогенного репродуктивно-респираторного синдрома свиней (hp prrs)
TWI686475B (zh)	2020-03-01	對抗腸病毒感染之基於腺病毒載體之疫苗
Renukaradhya et al.	2012	Mucosal vaccines to prevent porcine reproductive and respiratory syndrome: a new perspective
Zhang et al.	2018	Characterization of an inactivated whole-virus bivalent vaccine that induces balanced protective immunity against coxsackievirus A6 and A10 in mice
Diaz-San Segundo et al.	2014	Poly ICLC increases the potency of a replication-defective human adenovirus vectored foot-and-mouth disease vaccine
WO2019172982A1 (en)	2019-09-12	Attenuated flaviviruses
Bello et al.	2022	Recent progress and advances towards developing enterovirus 71 vaccines for effective protection against human hand, foot and mouth disease (HFMD)
NO328680B1 (no)	2010-04-26	Anvendelse av oral poliovirusvaksine (OPV) og ikke-polio enterovirusvaksine mot ikke-polio virussykdommer slik som type 1 diabetes og et vaksinepreparat omfattende nevnte virus.
CN119698293A (zh)	2025-03-25	重组猪冠状病毒
US7972592B2 (en)	2011-07-05	Prevention of type 1 diabetes and other non-polio enterovirus diseases
ES2748555T3 (es)	2020-03-17	Vacuna contra la rinitis equina
EP4288526A1 (de)	2023-12-13	Abgeschwächtes afrikanisches schweinepestvirus und seine verwendung als impfstoff
US11633468B2 (en)	2023-04-25	Multi-CBV vaccine for preventing or treating type 1 diabetes
US12161713B2 (en)	2024-12-10	Prime-boost vaccination regimen
Bourne et al.	2015	Control and eradication of human and animal diseases by vaccination